The Phase 1 trial of ER-100, which activates Yamanaka factors in the eye, did not cause serious adverse events in three participants. Early visual field signals were observed in two of the three patients with open-angle glaucoma.
The Phase 1 trial of ER-100, which activates Yamanaka factors in the eye, did not cause serious adverse events in three participants. Early visual field signals were observed in two of the three patients with open-angle glaucoma.